Joris Vos

11PUBLICATIONS
81CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 28, 2026
Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head and Neck Cancer.

Manu Prasad, Alex T Cheng, Marcel Mayer

|Oct 08, 2025
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Sabine E Breukers, Joleen J H Traets, Stan W van Dijk

|Jun 02, 2025
Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination.

Karena Zhao, Joris Vos, Stanley Lam

|Jan 06, 2025
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.

Seong-Keun Yoo, Conall W Fitzgerald, Byuri Angela Cho

|Oct 01, 2024
Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma.

Antoine Desilets, Joris L Vos, Nora Katabi

|Mar 22, 2024
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.

Alberto Gil-Jimenez, Nick van Dijk, Joris L Vos

Pageof 2

Frequent Collaborators

5 joint publications

Luc G T Morris

4 joint publications

Fengshen Kuo

4 joint publications

Charlotte L Zuur

3 joint publications

Xiaohang Qiao